Preclinical biodistribution and toxicology assessment of an AAV5-based subretinal modifier gene therapy for retinitis pigmentosaArun K. Upadhyay(Indian Institute of Technology Bhilai), Rasappa ArumughamFrontiers in MedicineOctober 29, 202510.3389/fmed.2025.1679619Cited by 0SaveCiteExport RISWatch citationsRelated PapersPreclinical dose response study shows NR2E3 can attenuate retinal degeneration in the retinitis pigmentosa mouse model RhoP23H+/−|Gene Therapy|2024|10Evaluating therapeutic potential of NR2E3 doses in the rd7 mouse model of retinal degeneration|Scientific Reports|2024|3